AstraZeneca 與 Jacobio 合作開發及商業化 SHP2 抑制劑用於癌症治療

This collaboration could unlock new treatment paradigms for advanced solid tumors by combining SHP2 and MEK inhibitors.

2026年3月12日

2 min read

規範來源

标准覆盖65%

LinkedIn X

核心变化

阿斯利康与Jacobio宣布合作共同开发和商业化用于癌症治疗的SHP2抑制剂，并启动联合疗法的临床试验。

Source Report— Original information from the primary source.

AstraZeneca 已與 Jacobio Pharma 簽訂臨床試驗合作及供應協議。該合作旨在評估 Jacobio 的 SHP2 抑制劑 JAB-3312 與 AstraZeneca 的 MEK 抑制劑 selumetinib 聯合治療晚期實體瘤患者的潛力。此次合作將探索在癌症治療中同時靶向 SHP2 和 MEK 通路的潛在協同效應。

Read Full Source →

Sigvera Intelligence— Our analysis and strategic assessment of this development.

核心要點

1AstraZeneca and Jacobio are collaborating on a clinical trial for advanced solid tumors.

2The trial will test the combination of Jacobio's SHP2 inhibitor (JAB-3312) and AstraZeneca's MEK inhibitor (selumetinib).

3The partnership includes a clinical trial collaboration and a supply agreement.

4The collaboration aims to explore the synergistic effects of targeting SHP2 and MEK pathways.

Strategic Implications

Market Impact

This collaboration could unlock new treatment paradigms for advanced solid tumors by combining SHP2 and MEK inhibitors. Success in these trials may lead to more effective combination therapies, potentially addressing unmet needs in oncology and strengthening AstraZeneca's position in the precision medicine market.

Industry Context

健康科技与生物技术

Where this signal fits in the broader landscape.

110 条行业信号合作

查看全部

Company Activity

查看全部

Mar 12, 2026監管與政策

AstraZeneca 的 Datopotamab Deruxtecan 在美國獲得轉移性肺癌的快速審查資格

Mar 12, 2026監管與政策

AstraZeneca的Enhertu獲美國優先審查，用於HER2陽性早期乳癌新輔助治療後

Mar 12, 2026合作